Spots Global Cancer Trial Database for Safety and Efficacy Assessments of Osalmid in Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Efficacy Assessments of Osalmid in Multiple Myeloma
Official Title: Safety and Efficacy Assessments of Osalmid in the Treatment of Multiple Myeloma
Study ID: NCT03670173
Conditions
Interventions
Study Description
Brief Summary: This study aims to evaluate the safety and efficacy of a traditional cholagogue drug osalmid, 2-hydroxy-N-(4-hydroxyphenyl)-benzamide, in the treatment of multiple myeloma (MM).
Detailed Description: Osalmid, 2-hydroxy-N-(4-hydroxyphenyl)-benzamide, is a traditional cholagogue and is clinically used in China to promote biliary drainage and protect liver function. Studies have shown that osalmid is an inhibitor of ribonucleotide reductase (RR). Recently, it was proven by our group that osalmid induced a dose-dependent lethality in multiple myeloma (MM) cell lines H929, OPM2, U266, OCI-MY5, and RPMI 8266, as well as in MM xenograft mouse models. This study aims to assess the safety and efficacy of osalmid in the treatment of MM.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Shanghai 10th People's Hospital, Shanghai, Shanghai, China
Contact Details
Name: Jumei Shi, MD PhD
Affiliation: Shanghai 10th People's Hospital
Role: STUDY_DIRECTOR
Name: Weiliang Zhu, PhD
Affiliation: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
